Audeo Oncology (Audeo Oncology) Liabilities-to-Assets : 0.74 (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Audeo Oncology's Total Liabilities for the quarter that ended in Sep. 2012 was $5.74 Mil. Audeo Oncology's Total Assets for the quarter that ended in Sep. 2012 was $7.81 Mil. Therefore, Audeo Oncology's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2012 was 0.74.

Audeo Oncology Liabilities-to-Assets Historical Data

The historical data trend for Audeo Oncology's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Liabilities-to-Assets Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Liabilities-to-Assets

99.38

25.25

0.28

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Liabilities-to-Assets	25.25	18.72	0.28	0.74

Competitive Comparison of Audeo Oncology's Liabilities-to-Assets

For the Drug Manufacturers - General subindustry, Audeo Oncology's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Liabilities-to-Assets falls into.

Audeo Oncology Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Audeo Oncology's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2012 is calculated as:

Liabilities-to-Assets (A: Jun. 2012 )	=	Total Liabilities	/	Total Assets
	=	2.679	/	9.712
	=	0.28

Audeo Oncology's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2012 is calculated as

Liabilities-to-Assets (Q: Sep. 2012 )	=	Total Liabilities	/	Total Assets
	=	5.744	/	7.805
	=	0.74

Audeo Oncology (DELISTED:AURX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Audeo Oncology Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Liabilities-to-Assets

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.